 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for OR51E2 |
 Gene summary |
| Basic gene information | Gene symbol | OR51E2 |
| Gene name | olfactory receptor, family 51, subfamily E, member 2 | |
| Synonyms | OR51E3P|OR52A2|PSGR | |
| Cytomap | UCSC genome browser: 11p15 | |
| Type of gene | protein-coding | |
| RefGenes | NM_030774.3, | |
| Description | HPRAJolfactory receptor 51E2olfactory receptor OR11-16olfactory receptor, family 51, subfamily E, member 3 pseudogeneolfactory receptor, family 52, subfamily A, member 2prostate specific G-protein coupled receptorprostate-specific G-protein coupled | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 611268 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000167332 | ||
| HPRD : 17736 | ||
| Vega : OTTHUMG00000133362 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_OR51E2 | |
| BioGPS: 81285 | ||
| Pathway | NCI Pathway Interaction Database: OR51E2 | |
| KEGG: OR51E2 | ||
| REACTOME: OR51E2 | ||
| Pathway Commons: OR51E2 | ||
| Context | iHOP: OR51E2 | |
| ligand binding site mutation search in PubMed: OR51E2 | ||
| UCL Cancer Institute: OR51E2 | ||
| Assigned class in TissGDB* | A | |
| Included tissue-specific gene expression resources | HPA,TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Prostate | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | PRAD | |
| Reference showing the relevant tissue of OR51E2 | The activation of OR51E1 causes growth suppression of human prostate cancer cells. Maßberg D, Jovancevic N, Offermann A, Simon A, Baniahmad A, Perner S, Pungsrinont T, Luko K, Philippou S, Ubrig B, Heiland M, Weber L, Altmüller J, Becker C, Gisselmann G, Gelis L, Hatt H. Oncotarget. 2016 Jul 26;7(30):48231-48249. doi: 10.18632/oncotarget.10197. (pmid:27374083) go to article | |
| Description by TissGene annotations | TissgsKTS CNV lost TissGeneKTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0043401 | steroid hormone mediated signaling pathway | 19389702 | GO:0050911 | detection of chemical stimulus involved in sensory perception of smell | 19389702 | GO:0043401 | steroid hormone mediated signaling pathway | 19389702 | GO:0050911 | detection of chemical stimulus involved in sensory perception of smell | 19389702 |
| Top |
| TissGeneExp for OR51E2 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| LIHC | -2.659096349 | -3.827508349 | 1.168412 | 1.27E-07 | 8.68E-07 |
| KIRC | 1.379732373 | -0.794334293 | 2.174066667 | 1.07E-16 | 6.15E-16 |
| PRAD | 9.227580344 | 5.584393805 | 3.643186538 | 2.86E-13 | 1.78E-11 |
| KICH | -0.308938349 | -1.343182349 | 1.034244 | 0.00295 | 0.005841689 |
| COAD | 0.06282842 | 1.817582267 | -1.754753846 | 7.41E-05 | 0.000278957 |
| Top |
| TissGene-miRNA for OR51E2 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for OR51E2 |
| TissGeneSNV for OR51E2 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.R222Q | SKCM | 4 |
| p.M184I | SKCM | 3 |
| p.S152F | SKCM | 3 |
| p.A22V | UCEC | 2 |
| p.A66G | BRCA | 2 |
| p.R164W | UCEC | 2 |
| p.G264E | SKCM | 2 |
| p.A118T | SKCM | 2 |
| p.S3F | SKCM | 2 |
| p.C63G | LUAD | 1 |
| p.V205D | LUAD | 1 |
| p.G245S | LUAD | 1 |
| p.G40E | SKCM | 1 |
| p.E51K | SKCM | 1 |
| p.P29S | LGG | 1 |
| p.E90K | LUAD | 1 |
| p.R272H | GBM | 1 |
| p.C168G | LIHC | 1 |
| p.G245D | BLCA | 1 |
| p.C240S | LUAD | 1 |
| p.F28V | ESCA | 1 |
| p.P284S | SKCM | 1 |
| p.G318* | STAD | 1 |
| p.A316V | UCEC | 1 |
| p.S73F | LUSC | 1 |
| p.L267V | LUSC | 1 |
| p.V273I | THYM | 1 |
| p.Y59H | THCA | 1 |
| p.R121H | BLCA | 1 |
| p.G207V | LUAD | 1 |
| p.R130H | UCEC | 1 |
| p.V26I | PRAD | 1 |
| p.R301Q | SKCM | 1 |
| p.V123L | LUAD | 1 |
| p.V224F | LUAD | 1 |
| p.A56S | COAD | 1 |
| p.R49K | SKCM | 1 |
| p.P128Q | BLCA | 1 |
| p.L83F | SKCM | 1 |
| p.P269H | BRCA | 1 |
| p.L60F | LUAD | 1 |
| p.M64V | SKCM | 1 |
| p.S107* | LUAD | 1 |
| p.R222Q | COAD | 1 |
| p.G264* | UCEC | 1 |
| p.M77K | LIHC | 1 |
| p.T76I | SKCM | 1 |
| p.F39I | LUAD | 1 |
| p.T239A | OV | 1 |
| p.Q315H | LUAD | 1 |
| p.H104Y | SKCM | 1 |
| p.A95V | BLCA | 1 |
| p.R121H | READ | 1 |
| p.A118V | SKCM | 1 |
| p.T223M | SKCM | 1 |
| p.P283S | SKCM | 1 |
| p.H23Y | SKCM | 1 |
| p.I221T | LGG | 1 |
| p.F218S | PAAD | 1 |
| p.V48I | BLCA | 1 |
| p.S53G | HNSC | 1 |
| p.C63Y | PRAD | 1 |
| p.G292A | GBM | 1 |
| p.R262H | READ | 1 |
| p.K163T | LIHC | 1 |
| p.M211I | KIRP | 1 |
| p.S32F | SKCM | 1 |
| p.H55R | LUSC | 1 |
| p.G18E | SARC | 1 |
| p.V26I | STAD | 1 |
| p.I298S | UCEC | 1 |
| p.R301L | OV | 1 |
| p.L97I | LGG | 1 |
| p.D311H | BLCA | 1 |
| p.G292V | LUAD | 1 |
| p.A66E | ESCA | 1 |
| p.G18* | LUAD | 1 |
| p.S174L | BRCA | 1 |
| Top |
| TissGeneCNV for OR51E2 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for OR51E2 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | AW948948 | PAXBP1-OR51E2 | chr21:34123782 | chr11:4710533 | |
| Chimerdb3.0 | FusionScan | PRAD | TCGA-HC-7820-01A | OR51E2-AMACR | 5'UTR-CDS | chr11:4718882 | chr5:34006004 |
| TCGAfusionPortal | PRADA | PRAD | TCGA-V1-A8MK-01A | OR51E2-C17orf48 | 3UTR-5UTR | Chr11:4701401 | Chr17:10608227 |
| Top |
| TissGeneNet for OR51E2 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| Top |
| TissGeneProg for OR51E2 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for OR51E2 |
| TissGeneDrug for OR51E2 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for OR51E2 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0376358 | Malignant neoplasm of prostate | 12 | BeFree |
| umls:C0600139 | Prostate carcinoma | 11 | BeFree |
| umls:C0033578 | Prostatic Neoplasms | 4 | BeFree,LHGDN |
| umls:C0027627 | Neoplasm Metastasis | 2 | BeFree |
| umls:C0282612 | Prostatic Intraepithelial Neoplasias | 2 | BeFree |
| umls:C1704272 | Benign Prostatic Hyperplasia | 2 | BeFree |
| umls:C0878500 | Intraepithelial Neoplasia | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |